Alloimmune haemolysis in a renal transplant recipient receiving sirolimus
نویسندگان
چکیده
Anaemia commonly occurs following renal transplantation related to surgical blood loss, myelosuppression from immunosuppressive agents, antimicrobial prophylaxis and persisting renal impairment. A rare cause of anaemia after solid organ transplantation is alloimmune haemolysis due to antibodies from donor-derived lymphocytes accompanying the donor organ. We report the case of a 27-year-old patient receiving sirolimus who developed alloimmune haemolysis related to passenger lymphocytes. Although this has previously been reported in renal transplant recipients receiving a variety of immunosuppressive agents [11], to our knowledge this is the first case described in a patient receiving sirolimus.
منابع مشابه
Unusual manifestation of cutaneous Leishmaniasis in a renal transplant recipient
Cutaneous leishmaniasis may present as unusual manifestations in renal transplant patients receiving immunosuppressive therapy. This misleading presentation, may delay the diagnosis and treatment. Moreover special caution must be taken in renal transplant recipients because of possible interactions between antimony compounds and cyclosporine metabolites. We report a 45-year old man with 5 years...
متن کاملDe novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recipients. We report on a 42-year-old male renal transplant recipient who lost his first graft after reduction of immunosuppressive treatment due to Kaposi sarcoma and who successfully underwent a second renal transplant 10 years later. The patient's current treatment consists of low-dose prednisone,...
متن کاملTherapeutic Drug Monitoring of Sirolimus,Correlation With Laboratory Parameters In Transplant Patients
Sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. Sirolimus must be used within a narrow therapeutic window. Due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. T...
متن کاملSirolimus-induced interstitial pneumonitis in a renal transplant recipient.
Sirolimus is a recently licensed immunosuppressant for organ transplantation that has been used as basic, adjuvant, or maintenance therapy for prevention of organ rejection. Well-known side effects of this agent are hyperlipidemia and bone marrow suppression. Interstitial pneumonitis is a relatively newly described adverse effect of the drug. A 43-year-old female recipient of a cadaveric kidney...
متن کاملاثر سیرولیموس در کاهش هیپرتروفی بطن چپ در گیرندگان کلیه پیوندی: کارآزمایی بالینی
Background: Persistence of left ventricular hypertrophy (LVH) in renal transplant recipients is associated with unfavorable outcomes. Calcineurin-inhibitor (CNI) nephrotoxicity is a major cause of morbidity and mortality after kidney transplantation. In this study we compared sirolimus (SRL) with calcineurin-inhibitor as primary immunosuppressants for the attenuation of left ventricular hypertr...
متن کامل